Company Information
Industry 制造业
Company Introduction 深圳翰宇药业股份有限公司是一家以生产经营多肽药物为主的高新技术企业.公司的主要产品有多肽药物制剂类的注射用胸腺五肽、注射用生长抑素、醋酸去氨加压素注射液、注射用特利加压素等.2008年-2009年,公司产品醋酸去氨加压素注射液连续2年的市场占有率排名第一,2007-2009年公司的注射用生长抑素市场占有率均排名第二,注射用胸腺五肽均排名前三;公司的特利加压素还被评选为国药励展全国药品交易会"2009中国十大处方药重磅新品".截止2010年底公司拥有发明专利2项,申请发明专利29项。
Main Business 多肽制剂及原料药
Legal Representative 曾少贵
Top Executives
董事长:曾少贵
副董事长:曾少强
董事:曾少彬,PINXIANG YU,唐洋明,杨笛
独立董事:许立勇,康志红,胡文言
Top 5 Shareholder
Shareholder name Nature Holding Date
曾少贵限售股+流通A股11.16%30/09/2024
曾少强限售股+流通A股7.15%30/09/2024
李秀兰流通A股3.88%30/09/2024
深圳市高新投集团有限公司流通A股2.99%30/09/2024
曾少彬限售股+流通A股2.46%30/09/2024
Company Secretary 杨笛
Solicitors 国浩律师(深圳)事务所
Auditors 立信会计师事务所(特殊普通合伙)
Tel No 0755-26588036
Fax No 0755-26588022
Website www.hybio.com.cn
Email hy@hybio.com.cn
Company Address
Register: 广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼
Office: 广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼
Listing Date 07/04/2011
Shares Capital
Shares Capital: 916,927,040
Total A Share: 916,927,040
Listed A Share: 628,946,640
Non-tradable A Share: 287,980,400
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.580
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 0.859
Market Capitalization(RMB) 11.103B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.